文献速递前列腺癌

前列腺癌抗体偶联药物相关肿瘤相关抗原表达的系统性分析

Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-12-24

本研究采用质谱和免疫组化比较前列腺癌原发灶与骨转移灶中HER2、NECTIN4、TROP2、PSMA、TF、STEAP1和B7H3的表达。匹配队列27对及独立非匹配队列(原发灶100例、骨转移灶49例)显示,B7H3、STEAP1和PSMA在原发灶和骨转移灶中均高表达且稳定,而其他抗原表达波动。B7H3、STEAP1和PSMA可能为原发灶和骨转移灶的主要靶点。

要点

  • B7H3、STEAP1和PSMA在原发灶与骨转移灶中均高表达且稳定。
  • 骨转移灶中TROP2、TF、PSMA、B7H3表达显著低于原发灶,HER2和STEAP1显著高于原发灶。
  • B7H3、STEAP1和PSMA两两组合对骨转移灶表达覆盖率较高(≥85%)。

核心结论

  • B7H3、STEAP1和PSMA可能是前列腺癌原发灶和骨转移灶的主要ADC靶点。
  • 前列腺癌TAA表达具有动态和异质性。

研究设计与样本

  • 采用质谱和免疫组化比较匹配队列(n=27对)中原发灶与骨转移灶的TAA表达。
  • 另用免疫组化在独立非匹配队列(原发灶n=100,骨转移灶n=49)中验证。
  • 免疫组化评估包括传统半定量、计算机辅助H-score和归一化膜比率分析。

主要发现

  • 匹配队列中B7H3、STEAP1和PSMA在原发灶和骨转移灶中持续高表达且稳定,其他TAA表达可能波动。
  • 非匹配队列中骨转移灶的TROP2、TF、PSMA和B7H3表达显著低于原发灶(均p<0.05)。
  • 非匹配队列中骨转移灶的HER2和STEAP1表达显著高于原发灶(均p<0.05)。
  • 骨转移灶中STEAP1、B7H3和PSMA高表达,STEAP1和B7H3呈现相对均匀的高膜表达模式。
  • B7H3、STEAP1和PSMA两两组合对骨转移灶的表达覆盖率较高(≥85%)。

关键数值与推荐

  • 匹配队列样本量n=27对;非匹配队列原发灶n=100、骨转移灶n=49。
  • 骨转移灶与原发灶TAA表达差异均p<0.05。
  • B7H3、STEAP1和PSMA两两组合对骨转移灶表达覆盖率≥85%。

临床怎么用

  • 可考虑将B7H3、STEAP1和PSMA作为前列腺癌ADC治疗的优先候选靶点。
  • 骨转移灶与原发灶TAA表达存在差异,靶点选择时需考虑转移灶表达谱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study is to better characterize the expression profiles of well-established tumor-associated antigen (TAA) for antibody-drug conjugates (ADC) in primary lesion (PL) and bone metastatic lesion(BML) of prostate cancer (PCa). METHODS: Mass spectrometry (MS) and immunohistochemistry (IHC) were used to comprehensively compare the expression of HER2, NECTIN4, TROP2, PSMA, TF, STEAP1 and B7H3 in the matched cohort (n = 27 pairs), which included matched PL and BML samples from the same patients. IHC was then used to validate the expression of these TAAs in another independent unmatched cohort, including PL (n = 100) and BML (n = 49). IHC assessment included traditional semi-quantitative evaluation, computer-assisted H-score assessment and normalized membrane ratio (NMR) analysis. RESULTS: B7H3, STEAP1 and PSMA consistently exhibited high and stable expression rate in matched PL and BML, whereas the expression levels of the other TAAs may fluctuate between the two status. In the unmatched cohort, the expression levels of TROP2, TF, PSMA, and B7H3 were significantly lower, while the expression levels of HER2 and STEAP1 were significantly higher in BML than in PL (all p < 0.05). Overall, STEAP1, B7H3 and PSMA exhibited high expression rates in BML, with STEAP1 and B7H3 depicting relatively homogeneous high membranous expression patterns. The co-expression of these TAAs was frequently observed. In the dual-TAA combination analysis, any pairwise combination among B7H3, STEAP1, and PSMA exhibited relatively high expression coverage(å 85%) for BML. CONCLUSIONS: B7H3, STEAP1, and PSMA might be the predominant targets in both PL and BML. Our findings reveal the dynamic and heterogeneous nature of TAA expression in PCa and may provide insights for integrating ADC-based targeted therapies into the existing treatment landscape for PCa.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Mulati Y, Shen Q, Chen Y, et al. Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer. Prostate Cancer Prostatic Dis. 2025. PMID: 41444470. doi:10.1038/s41391-025-01066-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。